A simple high-performance liquid chromatography for determining lapatinib and erlotinib in human plasma.
Lapatinib and erlotinib are used for cancer treatment, showing large interindividual variability. Therapeutic drug monitoring may be useful for assessing the clinical outcomes and adverse events. A simple high-performance liquid chromatography ultraviolet method was developed for the determination of lapatinib and erlotinib in human plasma. An aliquot of plasma sample spiked with IS was treated with acetonitrile to precipitate the proteins. Lapatinib and erlotinib were separated on an octadecylsilyl silica-gel column using a mobile phase consisting of acetonitrile, methanol, water, and trifluoroacetic acid (26:26:48:0.1) pumped at a flow rate of 1.0 mL/min. The detection wavelength was set at 316 nm. The calibration curves for lapatinib and erlotinib were linear (r = 0.9999) in the range of 0.125-8.00 µg/mL. The extraction recoveries for both lapatinib and erlotinib at the plasma concentration of 0.125-8.00 µg/mL were higher than 89.9% with coefficients of variation (CVs) less than 3.5%. The CVs for intraday and interday assays of lapatinib and erlotinib were less than 5.1% and 6.1%, respectively. The present method can be used for blood concentration monitoring for lapatinib or erlotinib in exactly the same conditions.